Partnerships..."With its impressive clinical data coupled with its unique and novel mechanism, REOLYSIN will be an instrumental component in furthering the development of our oncology pipeline," said Carsten Lu, CEO of Adlai Nortye. "It immediately makes Adlai Nortye a late stage biotechnology company and REOLYSIN itself becomes our lead product. Given its potential in multiple oncological indications and its ability to be used in combination with multiple chemotherapies and immunotherapies, REOLYSIN will help to broaden future therapies made available by Adlai Nortye and advance us towards commercialization."
I wonder what happened for Adlai Nortye to no longer even list Pelareorep (aka Reolysin) in their pipeline, when in 2018 it was their lead candidate...
Share price is doing exactly what it does before any anticipated news event... it spikes three days before, flatlines for two days, then collapses on the day of the event... lets see shall we..